Hostname: page-component-cd9895bd7-fscjk Total loading time: 0 Render date: 2024-12-25T16:20:31.219Z Has data issue: false hasContentIssue false
  • English
  • Français

Cost comparison of zuclopenthixol acetate and haloperidol

Published online by Cambridge University Press:  02 January 2018

Clive E. Hyde ,
Colina Harrower-Wilson  and
Paul E. Ash
Clive E. Hyde*
Affiliation:
Department of Psychiatry, Withington Hospital, Nell Lane, West Didsbury, South Manchester M20 2LR
Colina Harrower-Wilson
Affiliation:
Department of Psychiatry, Withington Hospital, Nell Lane, West Didsbury, South Manchester M20 2LR
Paul E. Ash
Affiliation:
Department of Psychiatry, Withington Hospital, Nell Lane, West Didsbury, South Manchester M20 2LR
*
∗Correspondence
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

This prospective, sequential study compared the costs of using haloperidol or zuclopenthixol acetate for rapid tranquillisation. In the first phase, all 16 patients admitted to our psychiatric intensive care unit requiring rapid tranquillisation received haloperidol; in the second phase, all 26 such patients received zuclopenthixol acetate. Mean overall costs per patient were substantially lower in the zuclopenthixol acetate group than the haloperidol group, mainly because special nursing was used much less in the zuclopenthixol acetate group. All nursing staff preferred to use zuclopenthixol acetate rather than haloperidol. Zuclopenthixol acetate could potentially reduce the need for special nursing and produce valuable cost savings.

Type
Original papers
Information
Psychiatric Bulletin , Volume 22 , Issue 3 , March 1998 , pp. 140 - 143
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © 1998 The Royal College of Psychiatrists

References

Baastrup, P. C., Alhfors, U. G. & Bjerkenstedt, L. (1993) A controlled Nordic multicentre study of zuclopenthixol acetate in oil solution, haloperidol and zuclopenthixol in the treatment of acute psychosis. Acta Psychiatrica Scandinavica, 87, 48–58.Google Scholar
Berthot, B. D. & LaPierre, E. D. (1989) What does it mean? A new scale for rating patients' behaviour. Journal of Psychosocial Nursing, 27, 10–28.Google Scholar
Hyde, C. E. & Harrower-Wilson, C. (1995) Resource consumption in psychiatric intensive care: the cost of aggression. Psychiatric Bulletin, 19, 73–76.Google Scholar
Hyde, C. E. & Harrower-Wilson, C. & Morris, J. (1998) Violence, dissatisfaction and rapid tranquillisation in psychiatric intensive care. Psychiatric Bulletin (in press).CrossRefGoogle Scholar
Karson, C. N., McClellan, J. L. & Kashner, T. M. (1991) Assault increases the cost of care among inpatient veterans with schizophrenia. Journal of Nervous and Mental Disease, 179, 702–704.Google Scholar
Omérov, M., Wistedt, B. & Elgen, K. (1995) Treatment of acutely disturbed psychotic patients: assessment of new treatment strategy. Nordic Journal of Psychiatry, 49 (suppl. 35), 63–77.Google Scholar
Palmstierna, T. & Wistedt, B. (1987) Staff Observation Aggression Scale (SOAS): presentation and evaluation. Acta Psychiatrica Scandinavica, 76, 657–663.Google Scholar
Wistedt, B., Rasmussen, A., Rederson, L., et al (1990). The development of an observer scale for measuring social dysfunction and aggression (SDAS-11). Pharmacopsychiatry, 23, 249–252.Google Scholar
Yeasavage, J. A. (1982) In-patient violence and the schizophrenic patient: an inverse correlation between danger-related events and neuroleptic levels. Biological Psychiatry, 17, 1331–1337.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.